促红细胞生成素及其衍生物对神经保护作用的研究进展

Abstract
Figure/Table
References (36)
Related Citation (15)

Download: PDF (0 KB) HTML (48 KB)
Export: BibTeX | EndNote (RIS)

Abstract Erythropoietin(EPO)exerts an erythropoiesis effect by binding to the homodimer(EPOR)2 of the erythropoietin receptor(EPOR)and was initially used as an anemia treatment.In the past two decades,a large number of studies have confirmed that EPO can protect a variety of tissue systems,especially the nervous system,by anti-apoptosis,reducing inflammatory responses and supporting the reconstruction of damaged function by stimulating cell proliferation and differentiation.Further studies showed that the protective effect was mediated by EPOR/βCR,a heterodimer composed of EPOR and common β chain receptor(βCR).To avoid the side effects of erythropoiesis produced in the process of EPO treatment for tissue damage,different forms of EPO derivatives have been developed.This article aims to review the protective effects and mechanisms of EPO and its derivatives in the nervous system,hoping to provide guidance for the clinical application of EPO in neurological diseases.

Key words： Erythropoietin;Erythropoietin receptor;Common &beta chain receptor;Neuroprotection

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Ming-pei
	WANG Dan-dan
	XU Ming-bo
	YANG Zhong-fan
	CAO Rong-yue

Cite this article:

HU Ming-pei,WANG Dan-dan,XU Ming-bo, et al. Research progress of erythropoietin and its derivatives on neuroprotection[J]. 中国当代医药, 2021, 28(26): 46-50.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I26/46

[1]	许恒正，吴志猛，程孝中.促红细胞生成素对神经退行性疾病的作用[J].生物学杂志，2020，37（5）：94-98.
[5]	Wenger RH，Kurtz A.Erythropoietin[J].Compr Physiol，2011，1（4）：1759-1794.
[6]	Mcgraw K，List A.Erythropoietin Receptor Signaling and Lipid Rafts[J].Vitam Horm，2017，105：79-100.
[10]	Brines M，Cerami A.The receptor that tames the innate immune response[J].Mol Med，2012，18（3）：486-496.
[2]	Hemani S，Lane O，Agarwal S，et al.Systematic Review of Erythropoietin （EPO）for Neuroprotection in Human Studies[J].Neurochem Res，2021，46（4）：732-739.
[3]	Zhang C，Yang C，Zhu T.From Erythropoietin to Its Peptide Derivatives：Smaller but Stronger[J].Curr Protein Pept Sci，2017，18（12）：1191-1194.
[4]	Brines M.The therapeutic potential of erythropoiesis-stimulating agents for tissue protection：a tale of two receptors[J].Blood Purif，2010，29（2）：86-92.
[7]	Patel NS，Nandra KK，Thiemermann C.Bench-to-bedside review：Erythropoietin and its derivatives as therapies in critical care[J].Crit Care，2012，16（4）：229.
[8]	Brines M，Grasso G，Fiordaliso F，et al.Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor[J].Proc Natl Acad Sci USA，2004，101（41）：14907-14912.
[9]	Watowich SS.The eryth ropoietin receptor：molecular structure and hematopoietic signaling pathways[J].J Investig Med，2011，59（7）：1067-1072.
[11]	Martin L，Garcia Rodriguez J，Audran M，et al.Detection of a nonerythropoietic erythropoietin，Neuro-EPO，in blood after intranasal administration in rat[J].Drug Test Anal，2020，12（11-12）:1605-1613.
[12]	Santos-Morales O，Díaz-Machado A，Jiménez-Rodríguez D，et al.Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers：a randomized，parallel，open-label safety study[J].BMC Neurol，2017，17（1）：129.
[13]	Brines M，Patel NS，Villa P，et al.Nonerythropoietic，tissue-protective peptides derived from the tertiary structure of erythropoietin[J].Proc Natl Acad Sci USA，2008，105（31）：10 925-10 930.
[14]	Collino M，Thiemermann C，Cerami A，et al.Flipping the molecular switch for innate protection and repair of tissues：Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin[J].Pharmacol Ther，2015，151：32-40.
[15]	Ercan I，Tufekci K，Karaca E，et al.Peptide Derivatives of Erythropoietin in the Treatment of Neuroinflammation and Neurodegeneration[J].Adv Protein Chem Struct Biol，2018，112：309-357.
[16]	Nguyen AQ，Cherry BH，Scott GF，et al.Erythropoietin：powerful protection of ischemic and post-ischemic brain[J].Exp Biol Med（Maywood），2014，239（11）：1461-1475.
[17]	Dewan M，Serdar M，Van De Looij Y，et al.Repetitive Erythropoietin Treatment Improves Long-Term Neurocognitive Outcome by Attenuating Hyperoxia-Induced Hypomyelination in the Developing Brain[J].Front Neurol，2020，11：804.
[18]	Oorschot DE，Sizemore RJ，Amer AR.Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone，and Erythropoietin Combined with Hypothermia：History，Current Status，and Future Research[J].Int J Mol Sci，2020，21（4）：1487.
[19]	Xiong T，Qu Y，Mu D，et al.Erythropoietin for neonatal brain injury：opportunity and challenge[J].Int J Dev Neurosci，2011，29（6）：583-591.
[20]	Kimáková P，Solár P，Solárová Z，et al.Erythropoietin and its angiogenic activity[J].Int J Mol Sci，2017，18（7）：1519.
[21]	Urena-Guerrero M，Castaneda-Cabral J，Rivera-Cervantes M，et al.Neuroprotective and Neurorestorative Effects of Epo and VEGF：Perspectives for New Therapeutic Approaches to Neurological Diseases[J].Curr Pharm Des，2020，26（12）：1263-1276.
[22]	Karch CM，Cruchaga C，Goate AM.Alzheimer′s disease genetics：from the bench to the clinic[J].Neuron，2014，83（1）：11-26.
[23]	Benskey MJ，Perez RG，Manfredsson FP.The contribution of alpha synuclein to neuronal survival and function-Implications for Parkinson′s disease[J].J Neurochem，2016，137（3）：331-359.
[24]	Tysnes OB，Storstein A.Epidemiology of Parkinson′s disease[J].J Neural Transm（Vienna），2017，124（8）：901-905.
[32]	席召燕，段淑荣，陈明，等.氨甲酰促红细胞生成素的神经保护作用及机制的研究进展[J].现代生物医学进展，2019，19（5）：979-982.
[25]	Jang W，Kim HJ，Li H，et al.The neuroprotective effect of erythropoietin on rotenone-induced neurotoxicity in SHSY5Y cells through the induction of autophagy[J].Mol Neurobiol，2016，53（6）：3812-3821.
[26]	Jarero-Basulto JJ，Rivera-Cervantes MC，Gasca-Martínez D，et al.Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer′s Disease[J].Pharmaceuticals，2020，13（12）：424.
[27]	Park J，Lee SY，Shon J，et al.Adalimumab improves cognitive impairment，exerts neuroprotective effects and attenuates neuroinflammation in an Aβ1-40-injected mouse model of Alzheimer′s disease[J].Cytotherapy，2019，21（6）：671-682.
[28]	Bond WS，Rex TS.Evidence that erythropoietin modulates neuroinflammation through differential action on neurons，astrocytes，and microglia[J].Front Immunol，2014，5：523.
[29]	Carelli S，Giallongo T，Viaggi C，et al.Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors[J].Neuropharmacology，2017，119：76-90.
[30]	Carelli S，Giallongo T，Gombalova Z，et al.Counteracting neuroinflammation in experimental Parkinson′s disease favors recovery of function：Effects of Er-NPCs administration[J].J Neuroinflammation，2018，15（1）：1-17.
[31]	ReyF，OttolenghiS，GiallongoT，etal.MitochondrialMetabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson′s Disease[J].Antioxidants（Basel），2021，10（1）：121.
[33]	Peng B，Kong G，Yang C，et al.Erythropoietin and its derivatives：from tissue protection to immune regulation[J].Cell Death Dis，2020，11（2）：79.
[34]	Seeger N，Zellinger C，Rode A，et al.The erythropoietinderived peptide mimetic pHBSP affects cellular and cognitive consequences in a rat post-status epilepticus model[J].Epilepsia，2011，52（12）：2333-2343.
[35]	Heij L，Niesters M，Swartjes M，et al.Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy：a randomized，double-blind pilot study[J].Mol Med，2012，18（11）：1430-1436.
[36]	Brines M，Dunne AN，Van Velzen M，et al.ARA 290，a nonerythropoietic peptide engineered from erythropoietin，improves metabolic control and neuropathic symptoms in patients with type 2 diabetes[J].Mol Med，2014，20（1）：658-666.